Avatrombopag maleate is supplied as a crystalline pharmaceutical active ingredient under model codes ATB-M-API-020 for oral solid dosage and ATB-M-API-020S for injectable development. The molecule is a non-peptide thrombopoietin receptor agonist that can be processed into immediate-release tablets, capsules, granules, and injectable presentations. The maleate salt form is used for stoichiometric control and manufacturability; both model codes share the same chemical identity but differ in particle size distribution, bioburden, endotoxin control, residual solvent surveillance, and packaging configuration. The API is released under ICH Q7 cGMP and is suitable for finished-product manufacture under 21 CFR 210/211 and applicable pharmacopoeial dosage-form monographs. Because no dedicated USP-NF or Ph. Eur. monograph is assigned to this substance at the time of writing, the control strategy follows ICH Q6A, ICH Q3C, ICH Q3D, and validated analytical procedures under ICH Q2(R1).

Finished oral presentations in major jurisdictions include tablet strengths expressed as 20 mg avatrombopag free acid equivalent. The API is formulated by direct compression or dry granulation for tablet and capsule manufacture; granule intermediates may be produced by roller compaction to improve bulk density and flow. Injectable use is not established as a licensed presentation in all jurisdictions, and suitability is therefore determined through product-specific development rather than a compendial injectable monograph.

When the injectable grade enters an aseptic filling line

For injectable manufacture, the milled or micronized API is dissolved or suspended under aseptic conditions rather than subjected to terminal sterilization unless forced degradation studies demonstrate acceptable thermal stability. Aseptic processing is typically conducted in an ISO 14644-1 ISO 7 background with ISO 5 unidirectional airflow equivalent to EU GMP Grade A. If terminal sterilization is considered, a saturated steam cycle at 121 °C for 15 min should not be accepted without confirming chiral purity, total impurities, and assay stability. The maleate counterion can reduce pH in unbuffered aqueous systems; buffering to a physiologically acceptable range must be justified by pH-rate degradation data. Published data for this specific configuration is limited, so formulation development should include pH stress testing between pH 3.0 and pH 8.0, oxidation challenge with hydrogen peroxide, and photostability evaluation per ICH Q1B.

Filter compatibility for injectable processing should be established with polyethersulfone or polyvinylidene fluoride membranes at worst-case bioburden and differential pressure. If the API is processed as a suspension, particle size after autoclaving or aseptic milling must be re-qualified to confirm that D90 does not exceed the injectability threshold for the intended needle gauge. Endotoxin limits for the injectable grade are derived from the maximum intended daily dose using USP <85>; no universal endotoxin limit applies without a defined clinical dose and route. The oral grade is not interchangeable with the injectable grade because oral material is not released for sterility, endotoxin, or equivalent particulate matter control.

Solid-dose unit operations for tablet, capsule, and granule

Direct compression and dry granulation are the preferred solid-dosage routes because they minimize exposure to moisture and thermal stress. A low-dose 20 mg tablet formulation requires blend uniformity assessment under USP <905>, with stratified sampling across compression run times to detect segregation of fines. For capsules, low-shear tumble blending with order-of-addition controls is used to prevent appearance of agglomerates. Granule manufacture by roller compaction is acceptable when the API is pre-screened through a 0.5 mm sieve and blended with intragranular excipients before compaction. If wet granulation is proposed, a polymorph conversion study using X-ray powder diffraction is required because the maleate salt may undergo form change under aqueous stress. Published data for wet granulation of this API is limited; high-shear granulation should not be scaled up without confirming that dissolution and assay uniformity remain within specification over the full tableting campaign.

Magnesium stearate levels are typically held within 0.5–1.5 wt% of the final blend because excessive lubrication can reduce tensile strength and prolong disintegration. Tablet hardness and friability should be monitored under USP <1216> or equivalent, and dissolution should be controlled in 0.01 M hydrochloric acid and a higher pH medium only if the product is intended for modified release. The maleate salt is incompatible with strongly alkaline aqueous processing above pH 8.0 unless stability data demonstrate otherwise. Combination with sodium bicarbonate, croscarmellose sodium, or other basic excipients should be assessed for salt disproportionation and related substance formation during accelerated stability.

Relative to romiplostim, avatrombopag maleate is a chemically synthesized small molecule rather than a recombinant peptide-Fc fusion protein. This distinction permits oral tablet and capsule manufacture via conventional dry blending and compression, whereas romiplostim requires subcutaneous injection and a cold-chain distribution model. Relative to eltrombopag olamine, avatrombopag maleate does not carry the same polyvalent cation chelation restriction; therefore, dosing instructions do not require the same separation from calcium-, magnesium-, or iron-containing foods and supplements. These differences influence API handling, excipient selection, and packaging of the finished product, but they do not remove the need for product-specific stability and dissolution controls.

Why are residual solvent and elemental impurity budgets different between oral and injectable grades?

Compliance with ICH Q3C and ICH Q3D requires a combined gas chromatography and inductively coupled plasma mass spectrometry control strategy. Residual solvent acceptance criteria are set at Class 1 benzene ≤ 2 ppm, carbon tetrachloride ≤ 4 ppm, and 1,2-dichloroethane ≤ 5 ppm. Class 2 solvents commonly controlled include dichloromethane ≤ 600 ppm, methanol ≤ 3000 ppm, and toluene ≤ 890 ppm. Class 3 ethanol is controlled at ≤ 5000 ppm. The oral and injectable grades share the same chemical synthesis and therefore require the same residual solvent surveillance, but injectable processing may require additional controls for water and peroxide content because aqueous formulation can concentrate volatile impurities during lyophilization or sterile filtration.

Elemental impurity limits follow ICH Q3D option 1. For the oral grade, the daily permitted exposure for cadmium is ≤ 2 µg/day, lead ≤ 5 µg/day, arsenic ≤ 1.5 µg/day, and mercury ≤ 3 µg/day. For the injectable grade, cadmium is controlled at ≤ 0.6 µg/day, lead ≤ 5 µg/day, arsenic ≤ 1.5 µg/day, and mercury ≤ 0.3 µg/day. These are safety-based limits, not interchangeability limits, and the final drug product calculation must account for excipient contribution, container-closure leaching, and maximum daily dose.

The 0.3% total related substances limit for the injectable grade is tighter than the oral grade because injectable products require a more conservative impurity qualification strategy and because parenteral exposure bypasses first-pass metabolism. Specified degradation products above the ICH Q3A qualification threshold of 0.15% require toxicological qualification data. Any impurity with a reporting threshold below 0.05% should be included in the certificate of analysis if it is structurally related to the active molecule or the synthetic intermediate pool.

Particle size, polymorphism, and blend uniformity interactions

Laser diffraction particle size analysis under ISO 13320 is required for both grades. The oral grade is typically milled to a D90 ≤ 100 µm to balance blend uniformity and dissolution, while an injectable suspension may require a D90 ≤ 20 µm depending on needle gauge and syringeability. Published particle size limits for avatrombopag maleate in dry granulation are limited, so acceptance ranges should be derived from a design-of-experiments study across at least three batch scales. Poor flow due to a high proportion of particles below 10 µm can cause segregation and weight variation during high-speed tableting; addition of colloidal silicon dioxide at 0.2–0.5 wt% may reduce electrostatic fines migration but may also slow dissolution if over-blended.

Polymorphic form is controlled by X-ray powder diffraction. The crystalline pattern must be consistent with the designated form throughout the batch and after 24 months of storage. If a new form appears during roller compaction or wet granulation, dissolution and bioavailability should be re-evaluated. The maleate salt should be protected from high humidity during transfer. Pre-drying at RH < 40% is recommended when ambient room humidity exceeds 60%, and the API should not be exposed to direct steam or unbuffered alkaline cleaning solutions because these conditions can promote salt disproportionation or related substance formation.

Storage stability data generated under ICH Q1A(R2) should include long-term, intermediate, and accelerated conditions in the intended packaging configuration. Double polyethylene bags inside an aluminum foil laminate provide adequate moisture protection for oral-grade material. Injectable-grade material should be stored under controlled room temperature or refrigerated conditions based on stability data; the exact temperature shelf life must be supported by long-term data. The API should not be combined with strong oxidizing agents, and contact surfaces should be 316L stainless steel or equivalent to reduce metallic contamination. These controls are operational boundaries, not optional preferences, because the maleate salt is sensitive to moisture, alkaline pH, and oxidative conditions during storage and processing.